Menopause Pushes Into $10 Billion Market as Women Demand Better Care

2 articles · Updated · The New York Times · Jul 13

$10 billion-plus in menopause products and services is gaining momentum as menopausal and perimenopausal women turn a once-taboo life stage into a public demand for better healthcare.
Celebrity advocacy from Melinda French Gates, Halle Berry, Kate Winslet, Olivia Wilde and Penélope Cruz is helping normalize discussion of perimenopause and hormonal treatment, widening the audience for research and consumer offerings.
That cultural shift is colliding with a healthcare system where most women with menopausal symptoms still receive no treatment, with Black and Hispanic women facing the weakest support despite earlier menopause and heavier health consequences.
The broader change builds on rising investment in women's health, but it also sharpens a central question for the fast-growing sector: whether new menopause attention will deliver evidence-based care rather than branding alone.

Sources

Left100%

The New York Times3d ago

Menopause Revolution: Women, Celebrities, and $10 Billion Market Demand Better Healthcare

Bloomberg5d ago

$360 Billion Women's Health Market Transforms with New Investments and FDA Policy

As menopause care becomes a billion-dollar industry, who profits most: patients or corporate investors?

Is the booming menopause market a true healthcare revolution or just a celebrity-fueled investment bubble?

With countless new menopause products, how can women find proven medical care amid the marketing hype?

2025 FDA Overhaul of HRT Warnings: Expanded Access, Market Growth, and Global Impact on Menopause Treatment

Overview

In November 2025, the FDA announced it would remove broad 'black box' warnings from most hormone replacement therapy (HRT) products, reflecting an evolving understanding of HRT and growing public awareness. Historically, these severe warnings deterred many postmenopausal women from using HRT due to fear, even though HRT can offer significant long-term health benefits. The FDA’s decision aims to provide women with more nuanced and comprehensive information, moving away from blanket cautions and encouraging informed discussions between patients and healthcare providers. This marks a pivotal shift in how HRT risks and benefits are communicated and understood.

...